Analysts' Top 5 Price Targets of March 5, 2025
Reading Time: 2 minutes
AxoGen [US05463X1063]: JMP Securities reaffirms Buy rating and raises the price target from $20 to $26 (39% upside potential) JMP Securities sees a promising future for the medical technology company AxoGen. One of the main reasons is the strategic positioning of the company in four significant markets: extremities, oral and maxillofacial surgery, breast, and prostate. These markets are expected to experience substantial growth, and AxoGen's innovative products, such as the Avance Nerve Graft, are well-positioned to capture a large share. An anticipated...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
